Association between cardiovascular-kidney-metabolic syndrome, inflammatory biomarkers, and cardiovascular outcomes: Insights from the MESA study
These findings suggest that systemic inflammation, as measured by IL-6, may modify the risk of ASCVD and HF associated with CKM syndrome. Therefore, IL-6 measurement could potentially refine risk stratification and prognosis of CKM syndrome stages. However, further studies are needed to assess the clinical relevance of this approach.
Authors
- Michael D. Shapiro (ORCID: https://orcid.org/0000-0002-9071-3287)
- Muhammad Imtiaz Ahmad (ORCID: https://orcid.org/0000-0002-6870-1722)
- Saeid Mirzai (ORCID: https://orcid.org/0000-0002-2579-4965)
- Roger S. Blumenthal (ORCID: https://orcid.org/0000-0003-1910-3168)
- Neha Jadeja Pagidipati (ORCID: https://orcid.org/0000-0002-5004-8868)
- Parag Anilkumar Chevli (ORCID: https://orcid.org/0000-0002-4084-8175)
- Garima Sharma (ORCID: https://orcid.org/0000-0003-0117-6000)
- Michael J. Blaha
- Khurram Nasir
- Joao Lima
- Jared Spitz (ORCID: https://orcid.org/0009-0005-3233-7833)
Institutions
- Inova Health System (US)
- Houston Methodist (US)
- Johns Hopkins University (US)
- Duke University (US)
- Medical College of Wisconsin (US)
- Johns Hopkins Medicine (US)
- Wake Forest University (US)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.120521
- Citations
- 1
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.35